Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

398 ARTÍCULOS , VIENDO DEL 166 AL 180

Phosphodiesterase inhibitors say NO to Alzheimer's disease

Nabavi SM, Talarek S, Listos J, Nabavi SF, Devi KP, Roberto de Oliveira M, Tewari D, Argüelles S, Mehrzadi S, Hosseinzadeh A, D'onofrio G, Orhan IE, Sureda A, Xu S, Momtaz S, Farzaei MH.

Food Chem Toxicol. 2019 Dec;134:110822. doi: 10.1016/j.fct.2019.110822. Epub 2019 Sep 16.

Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents

Pourshojaei Y, Eskandari K, Asadipour A.

Mini Rev Med Chem. 2019;19(19):1577-1598. doi: 10.2174/1389557519666190719143112.

Nutritional Interventions for Persons With Early-Stage Dementia or Alzheimer's Disease: An Integrative Review

Testad I, Kajander M, Froiland CT, Corbett A, Gjestsen MT, Anderson JG.

Res Gerontol Nurs. 2019 Sep 1;12(5):259-268. doi: 10.3928/19404921-20190813-02.

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Long JM, Holtzman DM.

Cell. 2019 Oct 3;179(2):312-339. doi: 10.1016/j.cell.2019.09.001. Epub 2019 Sep 26.

Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach

Dorababu A.

Bioorg Chem. 2019 Dec;93:103299. doi: 10.1016/j.bioorg.2019.103299. Epub 2019 Sep 19.

Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning

Kabir MT, Uddin MS, Begum MM, Thangapandiyan S, Rahman MS, Aleya L, Mathew B, Ahmed M, Barreto GE, Ashraf GM.

Curr Pharm Des. 2019;25(33):3519-3535. doi: 10.2174/1381612825666191008103141.

Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease

Morsy A, Trippier PC.

J Alzheimers Dis. 2019;72(s1):S145-S176. doi: 10.3233/JAD-190744.

NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy

Kabir MT, Sufian MA, Uddin MS, Begum MM, Akhter S, Islam A, Mathew B, Islam MS, Amran MS, Md Ashraf G.

Curr Pharm Des. 2019;25(33):3506-3518. doi: 10.2174/1381612825666191011102444.

Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies

Chen JY, Zhu Q, Zhang S, OuYang D, Lu JH.

Pharmacol Res. 2019 Dec;150:104476. doi: 10.1016/j.phrs.2019.104476. Epub 2019 Oct 9.

The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer's disease?

Rasmussen J.

Clin Interv Aging. 2019 Aug 15;14:1481-1492. doi: 10.2147/CIA.S211739. eCollection 2019.

Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease

Naushad M, Durairajan SSK, Bera AK, Senapati S, Li M.

Planta Med. 2019 Nov;85(17):1316-1325. doi: 10.1055/a-1019-9819. Epub 2019 Oct 16.

Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease

Dubey T, Chinnathambi S.

Arch Biochem Biophys. 2019 Nov 15;676:108153. doi: 10.1016/j.abb.2019.108153. Epub 2019 Oct 14.

Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease

Chan HH, Koh RY, Lim CL, Leong CO.

Curr Alzheimer Res. 2019;16(10):907-918. doi: 10.2174/1567205016666191023102422.

Anti-Alzheimer's Materials Isolated from Marine Bio-resources: A Review

Rathnayake AU, Abuine R, Kim YJ, Byun HG.

Curr Alzheimer Res. 2019;16(10):895-906. doi: 10.2174/1567205016666191024144044.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias